Hydatidiform Mole Management

Initial Diagnosis and Evaluation

The American College of Obstetricians and Gynecologists recommends that all patients with suspected hydatidiform mole require immediate quantitative serum β-hCG measurement, transvaginal ultrasound, complete blood count, comprehensive metabolic panel including liver function tests, thyroid function tests, blood type and screen, and chest X-ray 1
A complete mole is characterized by a heterogeneous intrauterine mass with multiple cystic spaces on ultrasound, and markedly elevated hCG often exceeding 100,000 mIU/mL 1
A partial mole is characterized by focal cystic placental changes with possible fetal tissue, and lower hCG levels 1
Thyroid function testing is critical as hyperthyroidism occurs due to hCG cross-reactivity with TSH receptors, particularly when hCG levels are markedly elevated 1

Suction dilation and curettage under ultrasound guidance is the standard treatment for all hydatidiform moles 2
The procedure should include suction aspiration followed by gentle sharp curettage, and blood products should be available due to significant hemorrhage risk 2
Administer Rho(D) immunoglobulin to all Rh-negative patients 3, 2, 1
Post-evacuation ultrasound or hysteroscopy should be performed to confirm complete evacuation 2

The UK protocol uses biweekly serum/urine hCG until normal, then monthly urine hCG 3
For complete hydatidiform mole, measure serum hCG weekly until undetectable, and continue monthly measurements for 6 months after normalization if hCG normalizes after 56 days 4, 3

Chemotherapy is indicated when hCG levels plateau or rise, or when there is evidence of metastatic disease 5, 3
The International Federation of Gynecology and Obstetrics recommends chemotherapy for patients with heavy vaginal bleeding requiring transfusion, evidence of gastrointestinal or intraperitoneal hemorrhage, or histological evidence of choriocarcinoma 5, 3

Complete moles have a 15-20% risk of developing gestational trophoblastic neoplasia, while partial moles have a 1-5% risk 2, 4
Approximately 2-3% of all hydatidiform moles progress to choriocarcinoma 2

Cure rates for gestational trophoblastic neoplasia approach 100% with appropriate treatment, and fertility is generally preserved 2

The American College of Obstetricians and Gynecologists recommends measuring serum β-hCG at least every 2 weeks until undetectable, with a critical prognostic indicator being the achievement of undetectable β-hCG levels and maintenance of them to prevent malignant disease 6
Chemotherapy is required if β-hCG plateaus, rises over two consecutive weekly measurements, or remains detectable beyond 6 months, with these indicators suggesting a higher risk of malignant transformation 6

The National Comprehensive Cancer Network guidelines suggest that chemotherapy is necessary if β-hCG levels do not decrease by at least 10% over three consecutive weekly measurements, indicating a potential for malignant transformation 6
The Society of Gynecologic Oncology recommends immediate evaluation with β-hCG measurement and ultrasound if any vaginal bleeding or symptoms occur between scheduled monitoring visits, to quickly identify potential invasive moles 6